BioCentury
ARTICLE | Clinical News

hPTH: Phase I data

July 16, 2007 7:00 AM UTC

In an open-label, dose-ranging, Dutch Phase I trial in 48 healthy post-menopausal women, once-daily transdermal hPTH (1-34) was well tolerated for 7 days and had a similar safety profile to subcutaneo...